Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Invitae | RCV001207357 | SCV001378702 | uncertain significance | Peroxisome biogenesis disorder 11A (Zellweger) | 2022-07-20 | criteria provided, single submitter | clinical testing | This sequence change replaces tyrosine, which is neutral and polar, with cysteine, which is neutral and slightly polar, at codon 93 of the PEX13 protein (p.Tyr93Cys). This variant is present in population databases (rs200211896, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with PEX13-related conditions. ClinVar contains an entry for this variant (Variation ID: 938182). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Fulgent Genetics, |
RCV002480677 | SCV002778201 | uncertain significance | Peroxisome biogenesis disorder 11A (Zellweger); Peroxisome biogenesis disorder 11B | 2022-02-25 | criteria provided, single submitter | clinical testing | |
| Ambry Genetics | RCV002561659 | SCV003685283 | uncertain significance | Inborn genetic diseases | 2021-07-26 | criteria provided, single submitter | clinical testing | The c.278A>G (p.Y93C) alteration is located in exon 2 (coding exon 2) of the PEX13 gene. This alteration results from a A to G substitution at nucleotide position 278, causing the tyrosine (Y) at amino acid position 93 to be replaced by a cysteine (C). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |